Germanium-Spirogermanium / eff Cancer Research Results

GeS, Germanium-Spirogermanium: Click to Expand ⟱

Features:

Spirogermanium — a synthetic germanium-containing organometallic small molecule developed as an investigational cytotoxic anticancer drug. It is an azaspirane compound formally identified as 2-[3-(dimethylamino)propyl]-8,8-diethyl-2-aza-8-germaspiro[4,5]decane and is commonly abbreviated SPG; historical identifiers include NSC-192965, Spiro-32 and S-99A. Unlike Ge-132 or propagermanium, spirogermanium was administered primarily by intravenous infusion as conventional experimental chemotherapy. It reached Phase I and Phase II oncology trials during the 1970s–1980s but was abandoned because objective responses were uncommon and dose-limiting neurotoxicity substantially restricted exposure.

Primary mechanisms (ranked):

Inhibition of cellular protein synthesis, reported as more sensitive to spirogermanium than RNA or DNA synthesis.
Broad suppression of RNA and DNA synthesis, producing non-cell-cycle-specific cytostatic or cytotoxic effects.
Direct tumor-cell cytotoxicity at approximately clinically achievable concentrations in selected experimental models, without a consistently demonstrated tumor-selective molecular target.
Neurological toxicity affecting central and peripheral nervous-system function, constituting the principal dose-limiting mechanism in humans.
Relative sparing of bone-marrow colony-forming cells compared with many conventional cytotoxic agents, resulting in limited myelosuppression despite substantial neurotoxicity.
Immunoregulatory effects reported in animal models, including induction of suppressor-cell activity, although these effects were not established as clinically useful anticancer mechanisms.

Bioavailability / PK relevance: Spirogermanium was evaluated predominantly by intravenous or intramuscular administration; oral supplement pharmacokinetics for Ge-132 do not apply. Effective and toxic exposure depended strongly on infusion duration and schedule. Slower two- to three-hour or continuous infusions permitted higher administered doses than short infusions, but neurological toxicity remained dose limiting. Historical intermittent Phase II regimens commonly used approximately 80–125 mg/m² per infusion, while five-day continuous-infusion studies evaluated approximately 150–250 mg/m²/day. Detailed modern human metabolism, transporter and exposure-response data remain limited.

In-vitro vs systemic exposure relevance: Experimental cytotoxicity was reported at approximately 1 µg/mL in several tumor models, but comparable concentrations were also toxic to cultured rat neurons. Therefore, in-vitro antitumor activity did not demonstrate a reliable therapeutic window. Clinical exposure produced neurological symptoms before broadly effective antitumor activity could be achieved. Spirogermanium is not appropriately interpreted as an oral germanium supplement or as a source of elemental germanium nutrition.

Clinical evidence status: Historical Phase I and Phase II investigational chemotherapy with no established contemporary clinical role. Isolated partial responses were reported in ovarian cancer, lymphoma, colorectal-cancer combination therapy, prostate cancer and other heavily pretreated populations, but most subsequent disease-specific studies reported no objective responses or only rare short-lived responses. Neurological toxicity was frequent and schedule dependent. Spirogermanium is not an approved anticancer drug, is not part of current standard oncology practice and has no active therapeutic development program identified.

Spirogermanium Mechanistic Profile

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Protein synthesis	↓ protein synthesis ↓ viability	↓ protein synthesis ↑ neuronal injury	R	Nonselective cytostatic and cytotoxic activity	Protein synthesis appeared more sensitive than RNA or DNA synthesis. The exact molecular target was not established.
2	RNA and DNA synthesis	↓ RNA synthesis ↓ DNA synthesis	↓ RNA synthesis ↓ DNA synthesis	R	Suppression of macromolecular synthesis	Spirogermanium was described as non-cell-cycle-specific rather than selectively active in one proliferative phase.
3	Direct tumor-cell cytotoxicity	↓ viability (model-dependent)	↓ neuronal viability	R	Experimental antineoplastic activity	Activity near 1 µg/mL was reported in selected tumor-cell lines, but neuronal toxicity at similar concentrations indicated a narrow therapeutic window.
4	Central and peripheral nervous system	↔ not tumor-selective	↑ dizziness ↑ ataxia ↑ paresthesia ↑ visual disturbance ↑ weakness	R	Dose-limiting neurotoxicity	Neurological toxicity was the principal clinical constraint and generally improved after interruption or withdrawal, although persistent taste loss or weakness occurred in some patients.
5	Bone-marrow progenitor cells	↓ leukemic-cell viability (model-dependent)	↔ marrow colony formation ↔ hematopoiesis	G	Relative marrow sparing	Limited myelosuppression distinguished spirogermanium from many historical cytotoxic drugs but did not compensate for its neurological toxicity or low response rate.
6	Exposure duration	↑ cytotoxicity with prolonged exposure	↑ neurological toxicity (dose-dependent)	G	Schedule-dependent therapeutic and toxic effects	Longer infusions allowed higher cumulative dosing and reduced some acute symptoms associated with rapid infusion, but did not establish a clinically adequate therapeutic index.
7	Immune suppressor-cell activity	↔ uncertain clinical effect	↑ suppressor-cell activity (model-dependent)	G	Experimental immunoregulation	Oral animal studies reported immunoregulatory and anti-inflammatory activity, but this was not established as a beneficial human anticancer mechanism.
8	Clinical Translation Constraint	↔ inconsistent responses ↓ efficacy in most tested tumors	↑ neurotoxicity ↔ limited myelosuppression	G	Unfavorable efficacy-to-toxicity balance	Small nonrandomized trials, heterogeneous schedules, rare responses and frequent neurological toxicity led to abandonment of clinical development.

P: 0–30 min R: 30 min–3 hr G: >3 hr

eff, efficacy: Click to Expand ⟱

Source:

Type:

Power to enhance an anti cancer effect

Scientific Papers found: Click to Expand⟱

7115-

GeS,

A phase II study of spirogermanium as second line therapy in patients with poor prognosis lymphoma. An NCI Canada Clinical Trials Group Study

Trial,

lymphoma,

eff↓, toxicity↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↓, 1,

Functional Outcomes(tgid=23) ⓘ

toxicity↝, 1,
Total Targets: 2

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: eff, efficacy

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells